Litcius/Paper detail

Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis

Adam S. Kittai, Ying Huang, Max J. Gordon, Nathan Denlinger, Agrima Mian, Lindsey Fitzgerald, Jennifer Bishop, Sarah Nagle, Deborah M. Stephens, Samantha Jaglowski, Brian T. Hill, Alexey V. Danilov

2020Transplantation and Cellular Therapy60 citationsDOI

Topics & Concepts

MedicineInternal medicineHazard ratioGastroenterologyDiffuse large B-cell lymphomaProportional hazards modelSurvival analysisLog-rank testLeukapheresisProgression-free survivalRefractory (planetary science)OncologyConfidence intervalLymphomaChemotherapyGeneticsStem cellCD34AstrobiologyPhysicsBiologyCAR-T cell therapy researchLymphoma Diagnosis and TreatmentIntegrated Circuits and Semiconductor Failure Analysis
Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis | Litcius